239 related articles for article (PubMed ID: 15963209)
21. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
Wilkinson DG; Passmore AP; Bullock R; Hopker SW; Smith R; Potocnik FC; Maud CM; Engelbrecht I; Hock C; Ieni JR; Bahra RS
Int J Clin Pract; 2002; 56(6):441-6. PubMed ID: 12166542
[TBL] [Abstract][Full Text] [Related]
22. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
Farlow MR
Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
[TBL] [Abstract][Full Text] [Related]
23. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
24. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
Burns A; Gauthier S; Perdomo C
Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
[TBL] [Abstract][Full Text] [Related]
26. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
27. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
28. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
Borkowska A; Ziolkowska-Kochan M; Rybakowski JK
Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
Campanozzi MD; Casali E; Neviani F; Martini E; Neri M
Arch Gerontol Geriatr; 2007; 44 Suppl 1():91-6. PubMed ID: 17317439
[TBL] [Abstract][Full Text] [Related]
30. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
Prescrire Int; 2001 Dec; 10(56):180-1. PubMed ID: 11824442
[TBL] [Abstract][Full Text] [Related]
31. Cholinesterase inhibitors in the treatment of dementia.
Ellis JM
J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
López-Pousa S; Olmo JG; Franch JV; Estrada AT; Cors OS; Nierga IP; Gelada-Batlle E
Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079
[TBL] [Abstract][Full Text] [Related]
33. Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors.
Erkinjuntti T; Román G; Gauthier S
J Neurol Sci; 2004 Nov; 226(1-2):63-6. PubMed ID: 15537522
[TBL] [Abstract][Full Text] [Related]
34. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
[TBL] [Abstract][Full Text] [Related]
35. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Kaduszkiewicz H; Zimmermann T; Beck-Bornholdt HP; van den Bussche H
BMJ; 2005 Aug; 331(7512):321-7. PubMed ID: 16081444
[TBL] [Abstract][Full Text] [Related]
36. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
Crowell TA; Paramadevan J; Abdullah L; Mullan M
J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):13-5. PubMed ID: 16449754
[TBL] [Abstract][Full Text] [Related]
37. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
38. Galantamine for Alzheimer's disease.
Prvulovic D; Hampel H; Pantel J
Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):345-54. PubMed ID: 20113148
[TBL] [Abstract][Full Text] [Related]
39. Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease.
Prescrire Int; 2003 Dec; 12(68):230-1. PubMed ID: 14986699
[TBL] [Abstract][Full Text] [Related]
40. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]